Allergan, Inc. and MAP Pharmaceuticals, Inc. entered into a definitive merger agreement whereby Allergan will acquire 100 percent of the shares of MAP Pharmaceuticals for a price of $25.00 per share. The acquisition is expected to close late in the first or second quarter of 2013.